Migraine Treatment Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (External Trigeminal Nerve Stimulation (e-TNS) Device, Single Pulse Transcranial Magnetic Stimulator (sTMS), gammaCore Non-Invasive Vagus Nerve Stimulator, Others), By Site (Handheld, Headband, Others), By Product Type (Prescription and Over The Counter), By Therapy (Acute Therapy and Preventive Therapy), By Distribution Channel (Hospital Based Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals & Clinics, Homecare, Others), By Region and Competition, 2019-2029F
Global Migraine Treatment Devices Market was valued at USD 748.64 Million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.03% through 2029. The Global Migraine Treatment Devices Market is primarily driven by a combination of factors including the increasing prevalence of migraine disorders, growing awareness about non-pharmacological treatment options, and technological advancements in device-based therapies. With migraine affecting millions of individuals worldwide, there is a rising demand for effective and convenient treatment modalities that can provide relief from symptoms such as headache, nausea, and sensitivity to light and sound. Device-based treatments such as transcranial magnetic stimulation (TMS), neuromodulation devices, and wearable gadgets offer non-invasive and drug-free alternatives to traditional migraine medications.
Key Market Drivers
Increasing Prevalence of Migraine Disorders
The escalating incidence of migraine disorders on a global scale stands as a formidable force propelling the expansion of the Global Migraine Treatment Devices Market. Migraine, an increasingly prevalent neurological condition, manifests through recurrent bouts of intense headaches, typically ranging from moderate to severe, frequently coupled with distressing symptoms like nausea, vomiting, and heightened sensitivity to light and sound. This neurological ailment imposes a significant burden on individuals' daily lives, affecting their productivity, well-being, and overall quality of life.
The surge in migraine prevalence can be attributed to multifaceted factors, including contemporary lifestyle changes, mounting stress levels, and inherent genetic predispositions. Modern-day stressors, such as hectic work schedules, environmental pressures, and societal demands, contribute to the exacerbation of migraine symptoms and the onset of new episodes. Genetic predispositions and familial histories of migraine further augment the susceptibility of individuals to this debilitating condition. As the global population grapples with the escalating prevalence of migraine disorders, there emerges an urgent and pressing need for effective treatment modalities that can mitigate symptoms and enhance the quality of life for migraine sufferers. Traditional pharmacological interventions, while widely utilized, may present limitations such as adverse side effects, medication overuse, and tolerance issues. Consequently, there is an increasing inclination towards exploring alternative treatment approaches that offer safe, non-invasive, and sustainable relief from migraine symptoms.
Growing Awareness about Non-Pharmacological Treatment Options
There is a growing awareness among healthcare professionals and patients about the benefits of non-pharmacological treatment options for migraine management, driving the demand for migraine treatment devices. While traditional pharmacological therapies such as painkillers and preventive medications remain widely used, there is increasing recognition of the limitations and side effects associated with long-term drug therapy. Device-based treatments offer non-invasive and drug-free alternatives for migraine relief, appealing to patients who prefer holistic approaches to managing their condition. Healthcare providers are increasingly recommending device-based therapies as adjunctive or standalone treatments for migraine, further fueling the adoption of migraine treatment devices in clinical practice.
Technological Advancements in Device-Based Therapies
Technological advancements play a pivotal role in driving innovation and expanding the capabilities of migraine treatment devices, enhancing their effectiveness and usability. Over the years, there has been significant progress in the development of advanced technologies such as transcranial magnetic stimulation (TMS), neuromodulation devices, and wearable gadgets designed specifically for migraine management. These devices leverage cutting-edge technology to target key areas of the brain involved in migraine pathophysiology, providing precise and targeted therapy to alleviate symptoms and prevent migraine attacks. Advancements in miniaturization, wireless connectivity, and user interface design have led to the development of portable and user-friendly migraine treatment devices that offer greater convenience and flexibility for patients.
Growing Demand for Alternative Migraine Treatment Options
There is a growing demand for alternative treatment options among migraine sufferers who seek alternatives to traditional pharmacological therapies. Device-based treatments offer a promising avenue for migraine management, providing patients with non-invasive and drug-free alternatives that complement or replace conventional medications. Many migraine sufferers experience limitations or adverse effects with pharmacological treatments, such as medication overuse headache (MOH) or tolerance to medication, prompting them to seek alternative solutions. Device-based therapies offer a safe and effective alternative for migraine relief, addressing the underlying mechanisms of migraine without the risk of medication-related side effects. As a result, there is increasing interest and demand for migraine treatment devices among patients and healthcare providers seeking alternative approaches to migraine management.
Key Market Challenges
Limited Clinical Evidence and Long-Term Efficacy Data
The limited availability of robust clinical evidence and long-term efficacy data poses a significant challenge for stakeholders in the Global Migraine Treatment Devices Market. While device-based therapies for migraine management show promise in clinical trials and real-world studies, the current body of evidence remains relatively sparse compared to pharmacological treatments. Many device-based therapies are relatively novel and have undergone limited long-term follow-up and post-market surveillance, making it challenging to assess their durability, safety profile, and sustained efficacy over time. Variability in study designs, patient populations, outcome measures, and follow-up periods across clinical trials further complicates data interpretation and generalizability. Generating comprehensive clinical evidence and real-world data on the long-term effectiveness, safety, and patient-reported outcomes of migraine treatment devices requires large-scale multicenter studies, patient registries, and collaborative research initiatives involving multiple stakeholders.
Patient Access and Affordability
Patient access and affordability represent significant challenges in the Global Migraine Treatment Devices Market, particularly in underserved and resource-limited settings. Despite the clinical benefits offered by migraine treatment devices, access barriers such as high upfront costs, limited insurance coverage, and out-of-pocket expenses hinder patient adoption and utilization. Many patients may face financial constraints or insurance limitations that prevent them from accessing device-based therapies for migraine management, leading to disparities in care and treatment outcomes. Lack of awareness, education, and provider familiarity with migraine treatment devices may further impede patient access and adoption. Addressing patient access and affordability challenges requires collaborative efforts among manufacturers, healthcare providers, payers, patient advocacy organizations, and policymakers to develop innovative financing models, patient assistance programs, and reimbursement strategies that ensure equitable access to migraine treatment devices for all patients in need.
Key Market Trends
Patient Preference for Non-Invasive Treatments
There is a growing preference among patients for non-invasive treatment options that offer relief from migraine symptoms without the need for surgery or medication. Device-based therapies align with this preference, providing non-invasive and drug-free alternatives that are generally well-tolerated and have minimal side effects. Patients appreciate the convenience, safety, and ease of use associated with migraine treatment devices, which can be used at home or on-the-go without the need for frequent clinic visits or invasive procedures. The autonomy and control afforded by device-based therapies empower patients to take an active role in managing their migraine symptoms, leading to greater patient satisfaction and adherence to treatment regimens.
Regulatory Approvals and Market Access Initiatives
The regulatory approval of migraine treatment devices by regulatory agencies such as the Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in Europe, and other regulatory authorities worldwide is a critical driver shaping the growth of the Global Migraine Treatment Devices Market. Regulatory approvals validate the safety, efficacy, and quality of migraine treatment devices, instilling confidence among healthcare providers and patients regarding their use in clinical practice. Market access initiatives, including reimbursement support, market authorization, and post-market surveillance programs, facilitate the widespread adoption and utilization of migraine treatment devices by ensuring patient access, coverage, and safety monitoring. Regulatory approvals and market access initiatives contribute to market growth by expanding patient access to device-based therapies and driving market penetration in key regions and healthcare settings.
Segmental Insights
TypeInsights
Based on the type, the gammaCore Non-Invasive Vagus Nerve Stimulator emerges as the dominant player, showcasing its prominence and widespread adoption across various healthcare settings. Developed by electroCore, Inc., gammaCore utilizes non-invasive vagus nerve stimulation (nVNS) technology to provide targeted therapy for migraine and cluster headache management. This handheld device delivers gentle electrical impulses to the vagus nerve through the skin, stimulating the nerve fibers and modulating the pain pathways associated with migraine attacks.
Several factors contribute to gammaCore's dominance in the Migraine Treatment Devices Market. gammaCore has garnered significant clinical validation and regulatory approvals, demonstrating its safety, efficacy, and therapeutic benefits in migraine management. Clinical studies and real-world evidence have showcased gammaCore's ability to reduce the frequency, severity, and duration of migraine attacks, offering patients relief from debilitating symptoms and improving their quality of life. gammaCore's non-invasive and user-friendly design makes it well-suited for home use, allowing patients to self-administer therapy at the onset of migraine symptoms or as a preventive measure, thereby empowering them to take control of their condition.
End User Insights
Based on the end user segment, homecare are emerging as the dominant domain, overshadowing hospitals and clinics in terms of market influence and adoption. This shift in dominance can be attributed to several key factors that underscore the growing preference for home-based migraine treatment solutions among patients and healthcare providers alike. The paradigm shift towards patient-centric care and self-management models has propelled the demand for homecare-based migraine treatment devices. Patients are increasingly seeking greater autonomy and control over their healthcare decisions, including the management of chronic conditions such as migraine. Homecare settings offer patients the convenience, comfort, and flexibility to administer migraine treatment at their own discretion, without the need for frequent clinic visits or healthcare provider supervision. This autonomy empowers patients to proactively manage their migraine symptoms, leading to improved treatment adherence, symptom control, and overall quality of life.
The rise of telemedicine and remote patient monitoring technologies has facilitated the delivery of healthcare services and support to patients in their homes. Telemedicine platforms enable patients to consult with healthcare providers, receive personalized treatment recommendations, and access educational resources from the comfort of their homes. Migraine treatment devices designed for home use complement these telemedicine initiatives, providing patients with effective therapeutic options that can be seamlessly integrated into their daily routines. As telemedicine continues to gain traction and acceptance, homecare-based migraine treatment devices are expected to witness further growth and adoption in the market.
Regional Insights
North America stands out as the dominating region, exerting significant influence and driving market growth with its robust healthcare infrastructure, technological advancements, and high prevalence of migraine disorders. Several key factors contribute to North America's dominance in the market, solidifying its position as a pivotal hub for innovation, research, and adoption of migraine treatment devices. North America boasts a well-established healthcare ecosystem characterized by advanced medical facilities, cutting-edge research institutions, and a strong regulatory framework. The region's healthcare infrastructure enables timely access to innovative medical technologies, including migraine treatment devices, and fosters collaborations between industry stakeholders, healthcare providers, and regulatory agencies. Regulatory bodies such as the Food and Drug Administration (FDA) in the United States and Health Canada set rigorous standards and requirements for the approval and commercialization of medical devices, ensuring patient safety and product efficacy.
North America's technologically advanced healthcare system fosters a culture of innovation and entrepreneurship, driving the development and adoption of novel migraine treatment devices. The region is home to a thriving medical device industry, comprising established manufacturers, start-ups, and research institutions dedicated to advancing migraine therapies. With a robust ecosystem of investors, venture capitalists, and research grants, North America facilitates the translation of scientific discoveries into commercialized products, accelerating the pace of innovation in the Migraine Treatment Devices Market.
Key Market Players
Theranica Bio-Electronics Ltd.
CEFALY Technology SPRL
ElectroCore, Inc.
eNeura Inc.
Neurolief Ltd.
Cirrus Healthcare Products LLC
Neuros Medical Inc.
Salvia BioElectronics B.V.
Theranica Bio-Electronics Ltd.
Dr Reddy's Laboratories Ltd.
Report Scope:
In this report, the Global Migraine Treatment Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Migraine Treatment Devices Market,By Type:
oExternal Trigeminal Nerve Stimulation (e-TNS) Device
oSingle Pulse Transcranial Magnetic Stimulator (sTMS)
ogammaCore Non-Invasive Vagus Nerve Stimulator
oOthers
Migraine Treatment Devices Market,By Site:
oHandheld
oHeadband
oOthers
Migraine Treatment Devices Market,By Product Type:
oPrescription
oOver The Counter
Migraine Treatment Devices Market,By Therapy:
oAcute Therapy
oPreventive Therapy
Migraine Treatment Devices Market,By Distribution Channel:
oHospital Based Pharmacies
oRetail Pharmacies
oOnline Pharmacies
Migraine Treatment Devices Market,By End User:
oHospitals Clinics
oHomecare
oOthers
Migraine Treatment Devices Market, By Region:
oNorth America
Company Profiles: Detailed analysis of the major companies present in the Global Migraine Treatment Devices Market.
Available Customizations:
Global Migraine Treatment Devices market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Key Market Drivers
Increasing Prevalence of Migraine Disorders
The escalating incidence of migraine disorders on a global scale stands as a formidable force propelling the expansion of the Global Migraine Treatment Devices Market. Migraine, an increasingly prevalent neurological condition, manifests through recurrent bouts of intense headaches, typically ranging from moderate to severe, frequently coupled with distressing symptoms like nausea, vomiting, and heightened sensitivity to light and sound. This neurological ailment imposes a significant burden on individuals' daily lives, affecting their productivity, well-being, and overall quality of life.
The surge in migraine prevalence can be attributed to multifaceted factors, including contemporary lifestyle changes, mounting stress levels, and inherent genetic predispositions. Modern-day stressors, such as hectic work schedules, environmental pressures, and societal demands, contribute to the exacerbation of migraine symptoms and the onset of new episodes. Genetic predispositions and familial histories of migraine further augment the susceptibility of individuals to this debilitating condition. As the global population grapples with the escalating prevalence of migraine disorders, there emerges an urgent and pressing need for effective treatment modalities that can mitigate symptoms and enhance the quality of life for migraine sufferers. Traditional pharmacological interventions, while widely utilized, may present limitations such as adverse side effects, medication overuse, and tolerance issues. Consequently, there is an increasing inclination towards exploring alternative treatment approaches that offer safe, non-invasive, and sustainable relief from migraine symptoms.
Growing Awareness about Non-Pharmacological Treatment Options
There is a growing awareness among healthcare professionals and patients about the benefits of non-pharmacological treatment options for migraine management, driving the demand for migraine treatment devices. While traditional pharmacological therapies such as painkillers and preventive medications remain widely used, there is increasing recognition of the limitations and side effects associated with long-term drug therapy. Device-based treatments offer non-invasive and drug-free alternatives for migraine relief, appealing to patients who prefer holistic approaches to managing their condition. Healthcare providers are increasingly recommending device-based therapies as adjunctive or standalone treatments for migraine, further fueling the adoption of migraine treatment devices in clinical practice.
Technological Advancements in Device-Based Therapies
Technological advancements play a pivotal role in driving innovation and expanding the capabilities of migraine treatment devices, enhancing their effectiveness and usability. Over the years, there has been significant progress in the development of advanced technologies such as transcranial magnetic stimulation (TMS), neuromodulation devices, and wearable gadgets designed specifically for migraine management. These devices leverage cutting-edge technology to target key areas of the brain involved in migraine pathophysiology, providing precise and targeted therapy to alleviate symptoms and prevent migraine attacks. Advancements in miniaturization, wireless connectivity, and user interface design have led to the development of portable and user-friendly migraine treatment devices that offer greater convenience and flexibility for patients.
Growing Demand for Alternative Migraine Treatment Options
There is a growing demand for alternative treatment options among migraine sufferers who seek alternatives to traditional pharmacological therapies. Device-based treatments offer a promising avenue for migraine management, providing patients with non-invasive and drug-free alternatives that complement or replace conventional medications. Many migraine sufferers experience limitations or adverse effects with pharmacological treatments, such as medication overuse headache (MOH) or tolerance to medication, prompting them to seek alternative solutions. Device-based therapies offer a safe and effective alternative for migraine relief, addressing the underlying mechanisms of migraine without the risk of medication-related side effects. As a result, there is increasing interest and demand for migraine treatment devices among patients and healthcare providers seeking alternative approaches to migraine management.
Key Market Challenges
Limited Clinical Evidence and Long-Term Efficacy Data
The limited availability of robust clinical evidence and long-term efficacy data poses a significant challenge for stakeholders in the Global Migraine Treatment Devices Market. While device-based therapies for migraine management show promise in clinical trials and real-world studies, the current body of evidence remains relatively sparse compared to pharmacological treatments. Many device-based therapies are relatively novel and have undergone limited long-term follow-up and post-market surveillance, making it challenging to assess their durability, safety profile, and sustained efficacy over time. Variability in study designs, patient populations, outcome measures, and follow-up periods across clinical trials further complicates data interpretation and generalizability. Generating comprehensive clinical evidence and real-world data on the long-term effectiveness, safety, and patient-reported outcomes of migraine treatment devices requires large-scale multicenter studies, patient registries, and collaborative research initiatives involving multiple stakeholders.
Patient Access and Affordability
Patient access and affordability represent significant challenges in the Global Migraine Treatment Devices Market, particularly in underserved and resource-limited settings. Despite the clinical benefits offered by migraine treatment devices, access barriers such as high upfront costs, limited insurance coverage, and out-of-pocket expenses hinder patient adoption and utilization. Many patients may face financial constraints or insurance limitations that prevent them from accessing device-based therapies for migraine management, leading to disparities in care and treatment outcomes. Lack of awareness, education, and provider familiarity with migraine treatment devices may further impede patient access and adoption. Addressing patient access and affordability challenges requires collaborative efforts among manufacturers, healthcare providers, payers, patient advocacy organizations, and policymakers to develop innovative financing models, patient assistance programs, and reimbursement strategies that ensure equitable access to migraine treatment devices for all patients in need.
Key Market Trends
Patient Preference for Non-Invasive Treatments
There is a growing preference among patients for non-invasive treatment options that offer relief from migraine symptoms without the need for surgery or medication. Device-based therapies align with this preference, providing non-invasive and drug-free alternatives that are generally well-tolerated and have minimal side effects. Patients appreciate the convenience, safety, and ease of use associated with migraine treatment devices, which can be used at home or on-the-go without the need for frequent clinic visits or invasive procedures. The autonomy and control afforded by device-based therapies empower patients to take an active role in managing their migraine symptoms, leading to greater patient satisfaction and adherence to treatment regimens.
Regulatory Approvals and Market Access Initiatives
The regulatory approval of migraine treatment devices by regulatory agencies such as the Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in Europe, and other regulatory authorities worldwide is a critical driver shaping the growth of the Global Migraine Treatment Devices Market. Regulatory approvals validate the safety, efficacy, and quality of migraine treatment devices, instilling confidence among healthcare providers and patients regarding their use in clinical practice. Market access initiatives, including reimbursement support, market authorization, and post-market surveillance programs, facilitate the widespread adoption and utilization of migraine treatment devices by ensuring patient access, coverage, and safety monitoring. Regulatory approvals and market access initiatives contribute to market growth by expanding patient access to device-based therapies and driving market penetration in key regions and healthcare settings.
Segmental Insights
TypeInsights
Based on the type, the gammaCore Non-Invasive Vagus Nerve Stimulator emerges as the dominant player, showcasing its prominence and widespread adoption across various healthcare settings. Developed by electroCore, Inc., gammaCore utilizes non-invasive vagus nerve stimulation (nVNS) technology to provide targeted therapy for migraine and cluster headache management. This handheld device delivers gentle electrical impulses to the vagus nerve through the skin, stimulating the nerve fibers and modulating the pain pathways associated with migraine attacks.
Several factors contribute to gammaCore's dominance in the Migraine Treatment Devices Market. gammaCore has garnered significant clinical validation and regulatory approvals, demonstrating its safety, efficacy, and therapeutic benefits in migraine management. Clinical studies and real-world evidence have showcased gammaCore's ability to reduce the frequency, severity, and duration of migraine attacks, offering patients relief from debilitating symptoms and improving their quality of life. gammaCore's non-invasive and user-friendly design makes it well-suited for home use, allowing patients to self-administer therapy at the onset of migraine symptoms or as a preventive measure, thereby empowering them to take control of their condition.
End User Insights
Based on the end user segment, homecare are emerging as the dominant domain, overshadowing hospitals and clinics in terms of market influence and adoption. This shift in dominance can be attributed to several key factors that underscore the growing preference for home-based migraine treatment solutions among patients and healthcare providers alike. The paradigm shift towards patient-centric care and self-management models has propelled the demand for homecare-based migraine treatment devices. Patients are increasingly seeking greater autonomy and control over their healthcare decisions, including the management of chronic conditions such as migraine. Homecare settings offer patients the convenience, comfort, and flexibility to administer migraine treatment at their own discretion, without the need for frequent clinic visits or healthcare provider supervision. This autonomy empowers patients to proactively manage their migraine symptoms, leading to improved treatment adherence, symptom control, and overall quality of life.
The rise of telemedicine and remote patient monitoring technologies has facilitated the delivery of healthcare services and support to patients in their homes. Telemedicine platforms enable patients to consult with healthcare providers, receive personalized treatment recommendations, and access educational resources from the comfort of their homes. Migraine treatment devices designed for home use complement these telemedicine initiatives, providing patients with effective therapeutic options that can be seamlessly integrated into their daily routines. As telemedicine continues to gain traction and acceptance, homecare-based migraine treatment devices are expected to witness further growth and adoption in the market.
Regional Insights
North America stands out as the dominating region, exerting significant influence and driving market growth with its robust healthcare infrastructure, technological advancements, and high prevalence of migraine disorders. Several key factors contribute to North America's dominance in the market, solidifying its position as a pivotal hub for innovation, research, and adoption of migraine treatment devices. North America boasts a well-established healthcare ecosystem characterized by advanced medical facilities, cutting-edge research institutions, and a strong regulatory framework. The region's healthcare infrastructure enables timely access to innovative medical technologies, including migraine treatment devices, and fosters collaborations between industry stakeholders, healthcare providers, and regulatory agencies. Regulatory bodies such as the Food and Drug Administration (FDA) in the United States and Health Canada set rigorous standards and requirements for the approval and commercialization of medical devices, ensuring patient safety and product efficacy.
North America's technologically advanced healthcare system fosters a culture of innovation and entrepreneurship, driving the development and adoption of novel migraine treatment devices. The region is home to a thriving medical device industry, comprising established manufacturers, start-ups, and research institutions dedicated to advancing migraine therapies. With a robust ecosystem of investors, venture capitalists, and research grants, North America facilitates the translation of scientific discoveries into commercialized products, accelerating the pace of innovation in the Migraine Treatment Devices Market.
Key Market Players
Theranica Bio-Electronics Ltd.
CEFALY Technology SPRL
ElectroCore, Inc.
eNeura Inc.
Neurolief Ltd.
Cirrus Healthcare Products LLC
Neuros Medical Inc.
Salvia BioElectronics B.V.
Theranica Bio-Electronics Ltd.
Dr Reddy's Laboratories Ltd.
Report Scope:
In this report, the Global Migraine Treatment Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Migraine Treatment Devices Market,By Type:
oExternal Trigeminal Nerve Stimulation (e-TNS) Device
oSingle Pulse Transcranial Magnetic Stimulator (sTMS)
ogammaCore Non-Invasive Vagus Nerve Stimulator
oOthers
Migraine Treatment Devices Market,By Site:
oHandheld
oHeadband
oOthers
Migraine Treatment Devices Market,By Product Type:
oPrescription
oOver The Counter
Migraine Treatment Devices Market,By Therapy:
oAcute Therapy
oPreventive Therapy
Migraine Treatment Devices Market,By Distribution Channel:
oHospital Based Pharmacies
oRetail Pharmacies
oOnline Pharmacies
Migraine Treatment Devices Market,By End User:
oHospitals Clinics
oHomecare
oOthers
Migraine Treatment Devices Market, By Region:
oNorth America
- United States
- Canada
- Mexico
- France
- United Kingdom
- Italy
- Germany
- Spain
- China
- India
- Japan
- Australia
- South Korea
- Brazil
- Argentina
- Colombia
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Migraine Treatment Devices Market.
Available Customizations:
Global Migraine Treatment Devices market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
1.PRODUCT OVERVIEW
1.1.Market Definition
1.2.Scope of the Market
1.2.1.Markets Covered
1.2.2.Years Considered for Study
1.2.3.Key Market Segmentations
2.RESEARCH METHODOLOGY
2.1.Objective of the Study
2.2.Baseline Methodology
2.3.Key Industry Partners
2.4.Major Association and Secondary Sources
2.5.Forecasting Methodology
2.6.Data Triangulation Validations
2.7.Assumptions and Limitations
3.EXECUTIVE SUMMARY
3.1.Overview of the Market
3.2.Overview of Key Market Segmentations
3.3.Overview of Key Market Players
3.4.Overview of Key Regions/Countries
3.5.Overview of Market Drivers, Challenges, Trends
4.VOICE OF CUSTOMER
5.GLOBAL MIGRAINE TREATMENT DEVICES MARKET OUTLOOK
5.1.Market Size Forecast
5.1.1.By Value
5.2.Market Share Forecast
5.2.1.By Type (External Trigeminal Nerve Stimulation (e-TNS) Device, Single Pulse Transcranial Magnetic Stimulator (sTMS), gammaCore Non-Invasive Vagus Nerve Stimulator, Others)
5.2.2.By Site (Handheld, Headband, Others)
5.2.3.By Product Type (Prescription and Over The Counter)
5.2.4.By Therapy (Acute Therapy and Preventive Therapy)
5.2.5.By Distribution Channel (Hospital Based Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.6.By End User (Hospitals Clinics, Homecare, Others)
5.2.7.By Region
5.2.8.By Company (2023)
5.3.Market Map
6.NORTH AMERICA MIGRAINE TREATMENT DEVICES MARKET OUTLOOK
6.1.Market Size Forecast
6.1.1.By Value
6.2.Market Share Forecast
6.2.1.ByType
6.2.2.By Site
6.2.3.By Product Type
6.2.4.By Therapy
6.2.5.By Distribution Channel
6.2.6.By End User
6.2.7.By Country
6.3.North America: Country Analysis
6.3.1.United States Migraine Treatment Devices Market Outlook
6.3.1.1.Market Size Forecast
6.3.1.1.1.By Value
6.3.1.2.Market Share Forecast
6.3.1.2.1.By Type
6.3.1.2.2.By Site
6.3.1.2.3.By Product Type
6.3.1.2.4.By Therapy
6.3.1.2.5.By Distribution Channel
6.3.1.2.6.By End User
6.3.2.Canada Migraine Treatment Devices Market Outlook
6.3.2.1.Market Size Forecast
6.3.2.1.1.By Value
6.3.2.2.Market Share Forecast
6.3.2.2.1.By Type
6.3.2.2.2.By Site
6.3.2.2.3.By Product Type
6.3.2.2.4.By Therapy
6.3.2.2.5.By Distribution Channel
6.3.2.2.6.By End User
6.3.3.Mexico Migraine Treatment Devices Market Outlook
6.3.3.1.Market Size Forecast
6.3.3.1.1.By Value
6.3.3.2.Market Share Forecast
6.3.3.2.1.By Type
6.3.3.2.2.By Site
6.3.3.2.3.By Product Type
6.3.3.2.4.By Therapy
6.3.3.2.5.By Distribution Channel
6.3.3.2.6.By End User
7.EUROPE MIGRAINE TREATMENT DEVICES MARKET OUTLOOK
7.1.Market Size Forecast
7.1.1.By Value
7.2.Market Share Forecast
7.2.1.By Type
7.2.2.By Site
7.2.3.By Product Type
7.2.4.By Therapy
7.2.5.By Distribution Channel
7.2.6.By End User
7.2.7.By Country
7.3.Europe: Country Analysis
7.3.1.Germany Migraine Treatment Devices Market Outlook
7.3.1.1.Market Size Forecast
7.3.1.1.1.By Value
7.3.1.2.Market Share Forecast
7.3.1.2.1.By Type
7.3.1.2.2.By Site
7.3.1.2.3.By Product Type
7.3.1.2.4.By Therapy
7.3.1.2.5.By Distribution Channel
7.3.1.2.6.By End User
7.3.2.United Kingdom Migraine Treatment Devices Market Outlook
7.3.2.1.Market Size Forecast
7.3.2.1.1.By Value
7.3.2.2.Market Share Forecast
7.3.2.2.1.By Type
7.3.2.2.2.By Site
7.3.2.2.3.By Product Type
7.3.2.2.4.By Therapy
7.3.2.2.5.By Distribution Channel
7.3.2.2.6.By End User
7.3.3.Italy Migraine Treatment Devices Market Outlook
7.3.3.1.Market Size Forecast
7.3.3.1.1.By Value
7.3.3.2.Market Share Forecasty
7.3.3.2.1.By Type
7.3.3.2.2.By Site
7.3.3.2.3.By Product Type
7.3.3.2.4.By Therapy
7.3.3.2.5.By Distribution Channel
7.3.3.2.6.By End User
7.3.4.France Migraine Treatment Devices Market Outlook
7.3.4.1.Market Size Forecast
7.3.4.1.1.By Value
7.3.4.2.Market Share Forecast
7.3.4.2.1.By Type
7.3.4.2.2.By Site
7.3.4.2.3.By Product Type
7.3.4.2.4.By Therapy
7.3.4.2.5.By Distribution Channel
7.3.4.2.6.By End User
7.3.5.Spain Migraine Treatment Devices Market Outlook
7.3.5.1.Market Size Forecast
7.3.5.1.1.By Value
7.3.5.2.Market Share Forecast
7.3.5.2.1.By Type
7.3.5.2.2.By Site
7.3.5.2.3.By Product Type
7.3.5.2.4.By Therapy
7.3.5.2.5.By Distribution Channel
7.3.5.2.6.By End User
8.ASIA-PACIFIC MIGRAINE TREATMENT DEVICES MARKET OUTLOOK
8.1.Market Size Forecast
8.1.1.By Value
8.2.Market Share Forecast
8.2.1.By Type
8.2.2.By Site
8.2.3.By Product Type
8.2.4.By Therapy
8.2.5.By Distribution Channel
8.2.6.By End User
8.2.7.By Country
8.3.Asia-Pacific: Country Analysis
8.3.1.China Migraine Treatment Devices Market Outlook
8.3.1.1.Market Size Forecast
8.3.1.1.1.By Value
8.3.1.2.Market Share Forecast
8.3.1.2.1.By Type
8.3.1.2.2.By Site
8.3.1.2.3.By Product Type
8.3.1.2.4.By Therapy
8.3.1.2.5.By Distribution Channel
8.3.1.2.6.By End User
8.3.2.India Migraine Treatment Devices Market Outlook
8.3.2.1.Market Size Forecast
8.3.2.1.1.By Value
8.3.2.2.Market Share Forecast
8.3.2.2.1.By Type
8.3.2.2.2.By Site
8.3.2.2.3.By Product Type
8.3.2.2.4.By Therapy
8.3.2.2.5.By Distribution Channel
8.3.2.2.6.By End User
8.3.3.Japan Migraine Treatment Devices Market Outlook
8.3.3.1.Market Size Forecast
8.3.3.1.1.By Value
8.3.3.2.Market Share Forecast
8.3.3.2.1.By Type
8.3.3.2.2.By Site
8.3.3.2.3.By Product Type
8.3.3.2.4.By Therapy
8.3.3.2.5.By Distribution Channel
8.3.3.2.6.By End User
8.3.4.South Korea Migraine Treatment Devices Market Outlook
8.3.4.1.Market Size Forecast
8.3.4.1.1.By Value
8.3.4.2.Market Share Forecast
8.3.4.2.1.By Type
8.3.4.2.2.By Site
8.3.4.2.3.By Product Type
8.3.4.2.4.By Therapy
8.3.4.2.5.By Distribution Channel
8.3.4.2.6.By End User
8.3.5.Australia Migraine Treatment Devices Market Outlook
8.3.5.1.Market Size Forecast
8.3.5.1.1.By Value
8.3.5.2.Market Share Forecast
8.3.5.2.1.By Type
8.3.5.2.2.By Site
8.3.5.2.3.By Product Type
8.3.5.2.4.By Therapy
8.3.5.2.5.By Distribution Channel
8.3.5.2.6.By End User
9.SOUTH AMERICA MIGRAINE TREATMENT DEVICES MARKET OUTLOOK
9.1.Market Size Forecast
9.1.1.By Value
9.2.Market Share Forecast
9.2.1.By Type
9.2.2.By Site
9.2.3.By Product Type
9.2.4.By Therapy
9.2.5.By Distribution Channel
9.2.6.By End User
9.2.7.By Country
9.3.South America: Country Analysis
9.3.1.Brazil Migraine Treatment Devices Market Outlook
9.3.1.1.Market Size Forecast
9.3.1.1.1.By Value
9.3.1.2.Market Share Forecast
9.3.1.2.1.By Type
9.3.1.2.2.By Site
9.3.1.2.3.By Product Type
9.3.1.2.4.By Therapy
9.3.1.2.5.By Distribution Channel
9.3.1.2.6.By End User
9.3.2.Argentina Migraine Treatment Devices Market Outlook
9.3.2.1.Market Size Forecast
9.3.2.1.1.By Value
9.3.2.2.Market Share Forecast
9.3.2.2.1.By Type
9.3.2.2.2.By Site
9.3.2.2.3.By Product Type
9.3.2.2.4.By Therapy
9.3.2.2.5.By Distribution Channel
9.3.2.2.6.By End User
9.3.3.Colombia Migraine Treatment Devices Market Outlook
9.3.3.1.Market Size Forecast
9.3.3.1.1.By Value
9.3.3.2.Market Share Forecast
9.3.3.2.1.By Type
9.3.3.2.2.By Site
9.3.3.2.3.By Product Type
9.3.3.2.4.By Therapy
9.3.3.2.5.By Distribution Channel
9.3.3.2.6.By End User
10.MIDDLE EAST AND AFRICA MIGRAINE TREATMENT DEVICES MARKET OUTLOOK
10.1.Market Size Forecast
10.1.1.By Value
10.2.Market Share Forecast
10.2.1.By Type
10.2.2.By Site
10.2.3.By Product Type
10.2.4.By Therapy
10.2.5.By Distribution Channel
10.2.6.By End User
10.2.7.By Country
10.3.MEA: Country Analysis
10.3.1.South Africa Migraine Treatment Devices Market Outlook
10.3.1.1.Market Size Forecast
10.3.1.1.1.By Value
10.3.1.2.Market Share Forecast
10.3.1.2.1.By Type
10.3.1.2.2.By Site
10.3.1.2.3.By Product Type
10.3.1.2.4.By Therapy
10.3.1.2.5.By Distribution Channel
10.3.1.2.6.By End User
10.3.2.Saudi Arabia Migraine Treatment Devices Market Outlook
10.3.2.1.Market Size Forecast
10.3.2.1.1.By Value
10.3.2.2.Market Share Forecast
10.3.2.2.1.By Type
10.3.2.2.2.By Site
10.3.2.2.3.By Product Type
10.3.2.2.4.By Therapy
10.3.2.2.5.By Distribution Channel
10.3.2.2.6.By End User
10.3.3.UAE Migraine Treatment Devices Market Outlook
10.3.3.1.Market Size Forecast
10.3.3.1.1.By Value
10.3.3.2.Market Share Forecast
10.3.3.2.1.By Type
10.3.3.2.2.By Site
10.3.3.2.3.By Product Type
10.3.3.2.4.By Therapy
10.3.3.2.5.By Distribution Channel
10.3.3.2.6.By End User
11.MARKET DYNAMICS
11.1.Drivers
11.2.Challenges
12.MARKET TRENDS DEVELOPMENTS
12.1.Merger Acquisition (If Any)
12.2.Product Launches (If Any)
12.3.Recent Developments
13.PORTER’S FIVE FORCES ANALYSIS
13.1.Competition in the Industry
13.2.Potential of New Entrants
13.3.Power of Suppliers
13.4.Power of Customers
13.5.Threat of Substitute Products
14.COMPETITIVE LANDSCAPE
14.1.Theranica Bio-Electronics Ltd.
14.1.1.Business Overview
14.1.2.Company Snapshot
14.1.3.Products Services
14.1.4.Financials (As Reported)
14.1.5.Recent Developments
14.1.6.Key Personnel Details
14.1.7.SWOT Analysis
14.2.CEFALY Technology SPRL
14.3.ElectroCore, Inc.
14.4.eNeura Inc.
14.5.Neurolief Ltd.
14.6.Cirrus Healthcare Products LLC
14.7.Neuros Medical Inc.
14.8.Salvia BioElectronics B.V.
14.9.Theranica Bio-Electronics Ltd.
14.10.Dr Reddy's Laboratories Ltd.
15.STRATEGIC RECOMMENDATIONS
16.ABOUT US DISCLAIMER
1.1.Market Definition
1.2.Scope of the Market
1.2.1.Markets Covered
1.2.2.Years Considered for Study
1.2.3.Key Market Segmentations
2.RESEARCH METHODOLOGY
2.1.Objective of the Study
2.2.Baseline Methodology
2.3.Key Industry Partners
2.4.Major Association and Secondary Sources
2.5.Forecasting Methodology
2.6.Data Triangulation Validations
2.7.Assumptions and Limitations
3.EXECUTIVE SUMMARY
3.1.Overview of the Market
3.2.Overview of Key Market Segmentations
3.3.Overview of Key Market Players
3.4.Overview of Key Regions/Countries
3.5.Overview of Market Drivers, Challenges, Trends
4.VOICE OF CUSTOMER
5.GLOBAL MIGRAINE TREATMENT DEVICES MARKET OUTLOOK
5.1.Market Size Forecast
5.1.1.By Value
5.2.Market Share Forecast
5.2.1.By Type (External Trigeminal Nerve Stimulation (e-TNS) Device, Single Pulse Transcranial Magnetic Stimulator (sTMS), gammaCore Non-Invasive Vagus Nerve Stimulator, Others)
5.2.2.By Site (Handheld, Headband, Others)
5.2.3.By Product Type (Prescription and Over The Counter)
5.2.4.By Therapy (Acute Therapy and Preventive Therapy)
5.2.5.By Distribution Channel (Hospital Based Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.6.By End User (Hospitals Clinics, Homecare, Others)
5.2.7.By Region
5.2.8.By Company (2023)
5.3.Market Map
6.NORTH AMERICA MIGRAINE TREATMENT DEVICES MARKET OUTLOOK
6.1.Market Size Forecast
6.1.1.By Value
6.2.Market Share Forecast
6.2.1.ByType
6.2.2.By Site
6.2.3.By Product Type
6.2.4.By Therapy
6.2.5.By Distribution Channel
6.2.6.By End User
6.2.7.By Country
6.3.North America: Country Analysis
6.3.1.United States Migraine Treatment Devices Market Outlook
6.3.1.1.Market Size Forecast
6.3.1.1.1.By Value
6.3.1.2.Market Share Forecast
6.3.1.2.1.By Type
6.3.1.2.2.By Site
6.3.1.2.3.By Product Type
6.3.1.2.4.By Therapy
6.3.1.2.5.By Distribution Channel
6.3.1.2.6.By End User
6.3.2.Canada Migraine Treatment Devices Market Outlook
6.3.2.1.Market Size Forecast
6.3.2.1.1.By Value
6.3.2.2.Market Share Forecast
6.3.2.2.1.By Type
6.3.2.2.2.By Site
6.3.2.2.3.By Product Type
6.3.2.2.4.By Therapy
6.3.2.2.5.By Distribution Channel
6.3.2.2.6.By End User
6.3.3.Mexico Migraine Treatment Devices Market Outlook
6.3.3.1.Market Size Forecast
6.3.3.1.1.By Value
6.3.3.2.Market Share Forecast
6.3.3.2.1.By Type
6.3.3.2.2.By Site
6.3.3.2.3.By Product Type
6.3.3.2.4.By Therapy
6.3.3.2.5.By Distribution Channel
6.3.3.2.6.By End User
7.EUROPE MIGRAINE TREATMENT DEVICES MARKET OUTLOOK
7.1.Market Size Forecast
7.1.1.By Value
7.2.Market Share Forecast
7.2.1.By Type
7.2.2.By Site
7.2.3.By Product Type
7.2.4.By Therapy
7.2.5.By Distribution Channel
7.2.6.By End User
7.2.7.By Country
7.3.Europe: Country Analysis
7.3.1.Germany Migraine Treatment Devices Market Outlook
7.3.1.1.Market Size Forecast
7.3.1.1.1.By Value
7.3.1.2.Market Share Forecast
7.3.1.2.1.By Type
7.3.1.2.2.By Site
7.3.1.2.3.By Product Type
7.3.1.2.4.By Therapy
7.3.1.2.5.By Distribution Channel
7.3.1.2.6.By End User
7.3.2.United Kingdom Migraine Treatment Devices Market Outlook
7.3.2.1.Market Size Forecast
7.3.2.1.1.By Value
7.3.2.2.Market Share Forecast
7.3.2.2.1.By Type
7.3.2.2.2.By Site
7.3.2.2.3.By Product Type
7.3.2.2.4.By Therapy
7.3.2.2.5.By Distribution Channel
7.3.2.2.6.By End User
7.3.3.Italy Migraine Treatment Devices Market Outlook
7.3.3.1.Market Size Forecast
7.3.3.1.1.By Value
7.3.3.2.Market Share Forecasty
7.3.3.2.1.By Type
7.3.3.2.2.By Site
7.3.3.2.3.By Product Type
7.3.3.2.4.By Therapy
7.3.3.2.5.By Distribution Channel
7.3.3.2.6.By End User
7.3.4.France Migraine Treatment Devices Market Outlook
7.3.4.1.Market Size Forecast
7.3.4.1.1.By Value
7.3.4.2.Market Share Forecast
7.3.4.2.1.By Type
7.3.4.2.2.By Site
7.3.4.2.3.By Product Type
7.3.4.2.4.By Therapy
7.3.4.2.5.By Distribution Channel
7.3.4.2.6.By End User
7.3.5.Spain Migraine Treatment Devices Market Outlook
7.3.5.1.Market Size Forecast
7.3.5.1.1.By Value
7.3.5.2.Market Share Forecast
7.3.5.2.1.By Type
7.3.5.2.2.By Site
7.3.5.2.3.By Product Type
7.3.5.2.4.By Therapy
7.3.5.2.5.By Distribution Channel
7.3.5.2.6.By End User
8.ASIA-PACIFIC MIGRAINE TREATMENT DEVICES MARKET OUTLOOK
8.1.Market Size Forecast
8.1.1.By Value
8.2.Market Share Forecast
8.2.1.By Type
8.2.2.By Site
8.2.3.By Product Type
8.2.4.By Therapy
8.2.5.By Distribution Channel
8.2.6.By End User
8.2.7.By Country
8.3.Asia-Pacific: Country Analysis
8.3.1.China Migraine Treatment Devices Market Outlook
8.3.1.1.Market Size Forecast
8.3.1.1.1.By Value
8.3.1.2.Market Share Forecast
8.3.1.2.1.By Type
8.3.1.2.2.By Site
8.3.1.2.3.By Product Type
8.3.1.2.4.By Therapy
8.3.1.2.5.By Distribution Channel
8.3.1.2.6.By End User
8.3.2.India Migraine Treatment Devices Market Outlook
8.3.2.1.Market Size Forecast
8.3.2.1.1.By Value
8.3.2.2.Market Share Forecast
8.3.2.2.1.By Type
8.3.2.2.2.By Site
8.3.2.2.3.By Product Type
8.3.2.2.4.By Therapy
8.3.2.2.5.By Distribution Channel
8.3.2.2.6.By End User
8.3.3.Japan Migraine Treatment Devices Market Outlook
8.3.3.1.Market Size Forecast
8.3.3.1.1.By Value
8.3.3.2.Market Share Forecast
8.3.3.2.1.By Type
8.3.3.2.2.By Site
8.3.3.2.3.By Product Type
8.3.3.2.4.By Therapy
8.3.3.2.5.By Distribution Channel
8.3.3.2.6.By End User
8.3.4.South Korea Migraine Treatment Devices Market Outlook
8.3.4.1.Market Size Forecast
8.3.4.1.1.By Value
8.3.4.2.Market Share Forecast
8.3.4.2.1.By Type
8.3.4.2.2.By Site
8.3.4.2.3.By Product Type
8.3.4.2.4.By Therapy
8.3.4.2.5.By Distribution Channel
8.3.4.2.6.By End User
8.3.5.Australia Migraine Treatment Devices Market Outlook
8.3.5.1.Market Size Forecast
8.3.5.1.1.By Value
8.3.5.2.Market Share Forecast
8.3.5.2.1.By Type
8.3.5.2.2.By Site
8.3.5.2.3.By Product Type
8.3.5.2.4.By Therapy
8.3.5.2.5.By Distribution Channel
8.3.5.2.6.By End User
9.SOUTH AMERICA MIGRAINE TREATMENT DEVICES MARKET OUTLOOK
9.1.Market Size Forecast
9.1.1.By Value
9.2.Market Share Forecast
9.2.1.By Type
9.2.2.By Site
9.2.3.By Product Type
9.2.4.By Therapy
9.2.5.By Distribution Channel
9.2.6.By End User
9.2.7.By Country
9.3.South America: Country Analysis
9.3.1.Brazil Migraine Treatment Devices Market Outlook
9.3.1.1.Market Size Forecast
9.3.1.1.1.By Value
9.3.1.2.Market Share Forecast
9.3.1.2.1.By Type
9.3.1.2.2.By Site
9.3.1.2.3.By Product Type
9.3.1.2.4.By Therapy
9.3.1.2.5.By Distribution Channel
9.3.1.2.6.By End User
9.3.2.Argentina Migraine Treatment Devices Market Outlook
9.3.2.1.Market Size Forecast
9.3.2.1.1.By Value
9.3.2.2.Market Share Forecast
9.3.2.2.1.By Type
9.3.2.2.2.By Site
9.3.2.2.3.By Product Type
9.3.2.2.4.By Therapy
9.3.2.2.5.By Distribution Channel
9.3.2.2.6.By End User
9.3.3.Colombia Migraine Treatment Devices Market Outlook
9.3.3.1.Market Size Forecast
9.3.3.1.1.By Value
9.3.3.2.Market Share Forecast
9.3.3.2.1.By Type
9.3.3.2.2.By Site
9.3.3.2.3.By Product Type
9.3.3.2.4.By Therapy
9.3.3.2.5.By Distribution Channel
9.3.3.2.6.By End User
10.MIDDLE EAST AND AFRICA MIGRAINE TREATMENT DEVICES MARKET OUTLOOK
10.1.Market Size Forecast
10.1.1.By Value
10.2.Market Share Forecast
10.2.1.By Type
10.2.2.By Site
10.2.3.By Product Type
10.2.4.By Therapy
10.2.5.By Distribution Channel
10.2.6.By End User
10.2.7.By Country
10.3.MEA: Country Analysis
10.3.1.South Africa Migraine Treatment Devices Market Outlook
10.3.1.1.Market Size Forecast
10.3.1.1.1.By Value
10.3.1.2.Market Share Forecast
10.3.1.2.1.By Type
10.3.1.2.2.By Site
10.3.1.2.3.By Product Type
10.3.1.2.4.By Therapy
10.3.1.2.5.By Distribution Channel
10.3.1.2.6.By End User
10.3.2.Saudi Arabia Migraine Treatment Devices Market Outlook
10.3.2.1.Market Size Forecast
10.3.2.1.1.By Value
10.3.2.2.Market Share Forecast
10.3.2.2.1.By Type
10.3.2.2.2.By Site
10.3.2.2.3.By Product Type
10.3.2.2.4.By Therapy
10.3.2.2.5.By Distribution Channel
10.3.2.2.6.By End User
10.3.3.UAE Migraine Treatment Devices Market Outlook
10.3.3.1.Market Size Forecast
10.3.3.1.1.By Value
10.3.3.2.Market Share Forecast
10.3.3.2.1.By Type
10.3.3.2.2.By Site
10.3.3.2.3.By Product Type
10.3.3.2.4.By Therapy
10.3.3.2.5.By Distribution Channel
10.3.3.2.6.By End User
11.MARKET DYNAMICS
11.1.Drivers
11.2.Challenges
12.MARKET TRENDS DEVELOPMENTS
12.1.Merger Acquisition (If Any)
12.2.Product Launches (If Any)
12.3.Recent Developments
13.PORTER’S FIVE FORCES ANALYSIS
13.1.Competition in the Industry
13.2.Potential of New Entrants
13.3.Power of Suppliers
13.4.Power of Customers
13.5.Threat of Substitute Products
14.COMPETITIVE LANDSCAPE
14.1.Theranica Bio-Electronics Ltd.
14.1.1.Business Overview
14.1.2.Company Snapshot
14.1.3.Products Services
14.1.4.Financials (As Reported)
14.1.5.Recent Developments
14.1.6.Key Personnel Details
14.1.7.SWOT Analysis
14.2.CEFALY Technology SPRL
14.3.ElectroCore, Inc.
14.4.eNeura Inc.
14.5.Neurolief Ltd.
14.6.Cirrus Healthcare Products LLC
14.7.Neuros Medical Inc.
14.8.Salvia BioElectronics B.V.
14.9.Theranica Bio-Electronics Ltd.
14.10.Dr Reddy's Laboratories Ltd.
15.STRATEGIC RECOMMENDATIONS
16.ABOUT US DISCLAIMER
